CLINICAL TRIALS PROFILE FOR IRBESARTAN AND HYDROCHLOROTHIAZIDE

All Clinical Trials for IRBESARTAN AND HYDROCHLOROTHIAZIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00095394 ↗	Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension	Completed	Sanofi	Phase 3	2004-09-01	The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095394 ↗	Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension	Completed	Bristol-Myers Squibb	Phase 3	2004-09-01	The purpose of this clinical research is to learn if severe hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095550 ↗	Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension	Completed	Sanofi	Phase 3	2004-10-01	The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00095550 ↗	Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension	Completed	Bristol-Myers Squibb	Phase 3	2004-10-01	The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.
NCT00110422 ↗	Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome	Completed	Sanofi	Phase 4	2005-11-01	The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome.

Clinical Trial Conditions for IRBESARTAN AND HYDROCHLOROTHIAZIDE

Condition Name

Condition Name for IRBESARTAN AND HYDROCHLOROTHIAZIDE
Intervention	Trials
Hypertension	13
Metabolic Syndrome	1
Microalbuminuria	1
Type 2 Diabetes	1

Condition MeSH

Condition MeSH for IRBESARTAN AND HYDROCHLOROTHIAZIDE
Intervention	Trials
Hypertension	12
Malnutrition	1
Albuminuria	1
Syndrome	1

Clinical Trial Locations for IRBESARTAN AND HYDROCHLOROTHIAZIDE

Trials by Country

Trials by Country for IRBESARTAN AND HYDROCHLOROTHIAZIDE
Location	Trials
United States	71
Canada	18
Germany	6
Taiwan	4
France	4

Trials by US State

Trials by US State for IRBESARTAN AND HYDROCHLOROTHIAZIDE
Location	Trials
Texas	4
Connecticut	2
Washington	2
Colorado	2
Virginia	2

Clinical Trial Progress for IRBESARTAN AND HYDROCHLOROTHIAZIDE

Clinical Trial Phase

Clinical Trial Phase for IRBESARTAN AND HYDROCHLOROTHIAZIDE
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	3
N/A	3

Clinical Trial Status

Clinical Trial Status for IRBESARTAN AND HYDROCHLOROTHIAZIDE
Clinical Trial Phase	Trials
Completed	15

Clinical Trial Sponsors for IRBESARTAN AND HYDROCHLOROTHIAZIDE

Sponsor Name

Sponsor Name for IRBESARTAN AND HYDROCHLOROTHIAZIDE
Sponsor	Trials
Sanofi	10
Bristol-Myers Squibb	4
Roxane Laboratories	2

Sponsor Type

Sponsor Type for IRBESARTAN AND HYDROCHLOROTHIAZIDE
Sponsor	Trials
Industry	16
Other	4